Biosciences sales rise 8% at CSL
This article was originally published in Clinica
Executive Summary
Australian company CSL's biosciences division has reported sales of Aus$12.5 million ($9.6 million) for fiscal 1995 (ended June 30th). The 8% growth in sales of core products - blood grouping reagents, infectious disease diagnostics and products for research laboratories - was able partly to offset the reduction in total revenue brought about by the transfer of the division's international cell culture business to JRH Biosciences which followed the acquisition of JRH by CSL in September 1994.